Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts

SIMPLE SUMMARY: There is a need to better understand the effectiveness of new treatments, such as the recently approved nivolumab, in patients with locally advanced or metastatic non-small cell lung cancer in clinical practice. This study aims to report the characteristics and outcomes of 2784 patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Chouaid, Christos, Thomas, Michael, Debieuvre, Didier, Durand-Zaleski, Isabelle, Zacharias, Stefan, Bosquet, Lise, Groth, Annika, Fleitz, Annette, Calleja, Alan, Patel, Sonya, Lacoin, Laure, Daumont, Melinda J., Penrod, John R., Carroll, Robert, Waldenberger, Daniela, Cotté, François-Emery, Audigier-Valette, Clarisse, Griesinger, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776880/
https://www.ncbi.nlm.nih.gov/pubmed/36551632
http://dx.doi.org/10.3390/cancers14246148

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776880/
https://www.ncbi.nlm.nih.gov/pubmed/36551632
http://dx.doi.org/10.3390/cancers14246148

Ejemplares similares